Baird downgrades Cooper Companies stock rating on weak sales

Baird downgraded Cooper Companies to Neutral from Outperform and cut its price target to $61 from $85, below the stock's $63.48 trading level. The downgrade followed weaker-than-expected Americas CooperVision organic growth of -2% year over year versus Baird's +6% estimate, alongside management's decision not to sell CSI because buyer interest was insufficient. Fiscal Q3 2026 adjusted EPS of $1.15 beat the $1.12 consensus, but revenue of $1.07B missed the $1.10B forecast, with CooperVision sales weakness and inventory reductions weighing on the near-term outlook.

Analysis

The key issue is not the near-term revenue miss but the earnings-algorithm reset: weaker volume through a distribution inventory correction removes operating leverage just as management is spending to restore growth. That combination can drive FY27 EBITDA/EPS estimate cuts even if underlying demand normalizes, leaving a superficially low forward multiple vulnerable to further compression. The cited valuation statistics are not directly comparable across GAAP and adjusted earnings, so the apparent “trough” valuation should not be treated as a floor without confirming the revised consensus EPS base.

The failed strategic-process outcome for CSI changes the capital-allocation debate. Retaining a slower-growth asset eliminates a potential deleveraging/buyback catalyst and raises the probability that management must fund reinvestment internally while defending margins. Over the next 1-3 months, sell-side estimate revisions and FY27 margin commentary matter more than another modest EPS beat; a return to positive Americas organic growth without incremental promotional spending would falsify the bearish setup. Over 6-18 months, improved channel sell-through could create a recovery trade, but competitive pressure in women’s health and the cost of rebuilding contact-lens growth argue against paying up before evidence appears.

Relative-value implications are more attractive than an outright sector short. ALGN and BLCO are imperfect but useful read-throughs: stable demand/price realization at either would isolate COO’s weakness as execution and channel-specific rather than a broad elective-eye-care slowdown. Conversely, deteriorating trends across those names would signal a more macro-sensitive consumer/healthcare utilization issue and reduce the appeal of a COO-specific short.

Key Decisions for Investors

• Maintain a bearish 1-3 month bias on COO, but do not chase the post-results decline; use rallies toward the revised analyst-target area around $61-$65 to initiate a tactical short or buy 3-month put spreads. Risk/reward improves only if consensus FY27 EPS has not yet been reset; cover on evidence of positive Americas organic growth plus stable gross-margin guidance.
• Consider a market-neutral pair: short COO / long ALC in equal dollar amounts for the next two earnings cycles. The thesis is COO-specific operating deleverage and capital-allocation uncertainty versus ALC’s relatively more diversified eye-care earnings base; exit if ALC also reports broad-based eye-care volume deterioration or COO raises margin guidance.
• Set an alert for post-quarter consensus revisions: a mid-single-digit or greater FY27 EPS cut, or incremental commentary on reinvestment, supports adding to the bearish position. Absence of estimate cuts despite weak revenue would indicate the downside may already be reflected and argues for no new trade.
• Avoid treating the reported 11-12x forward multiple as a standalone long trigger. Reassess for a 6-18 month long only after channel inventory normalizes, CSI’s strategic role is clarified, and management demonstrates that growth investment can be absorbed without a further EBIT-margin reset.